sc SC-560
- 公司名稱(chēng) MedChemExpress LLC
- 品牌 MedChemExpress (MCE)
- 型號(hào) sc
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2019/7/11 18:12:02
- 訪問(wèn)次數(shù) 608
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mM * 1 mL;5 mg;10 mg |
---|---|---|---|
貨號(hào) | HY-59105 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
SC-560
產(chǎn)品活性:SC-560是有效,選擇性的 COX-1 抑制劑,IC50 值為9 nM。
研究領(lǐng)域:Immunology/Inflammation
作用靶點(diǎn):COX
In Vitro: Preincubation of COX-1 with SC-560 inhibits the conversion of arachidonic acid to PGE2 in a concentration-dependent manner. The IC50 of SC-560 for COX-2 is 6.3 μM, nearly 1,000-fold higher than with COX-1. SC-560 shows a dose and time dependent inhibitory effect on HCC cell growth. SC-560 also inhibits colony formation in soft agar and induces apoptosis in HCC cells in a dose-dependent manner. Moreover, SC-560 decreases the levels of the anti-apoptotic proteins survivin and XIAP and activates caspase 3 and 7 in a dose and time dependent fashion.
In Vivo: Oral dosing with either 10 or 30 mg/kg SC-560 1 hour before assay completely inhibits ionophore-stimulated TxB2production, indicating that SC-560 is orally bioavailable and inhibits COX-1 in vivo. SC-560 extensively distributes into rat tissues, and has a CL approaching hepatic plasma flow. The drug displays low less than 15% and formulation dependent bioavailability after oral administration and demonstrates kidney toxicity.
相關(guān)產(chǎn)品:Anti-Aging Compound Library | Anti-Cancer Compound Library | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Celecoxib | Acetaminophen | Indomethacin | Aspirin | Ginsenoside Rg3 | Xanthohumol | Paradol | Diclofenac | Ibuprofen | Rofecoxib | (-)-Epicatechin gallate | Flufenamic acid | Ginsenoside C-K | Meloxicam | NS-398 | Salicylic acid | Carprofen | Ketoprofen | Catechin | Gallic acid | Parecoxib Sodium | Rutaecarpine | Sulindac | Nabumetone | Naproxen | Piroxicam | Diflunisal